Clinical Scorecard: Systematic Review of Whole-Exome Sequencing for Discovering Genetic Factors Linked to Severe Bacterial Infections
At a Glance
Category
Detail
Condition
Severe bacterial infections (SBIs)
Key Mechanisms
Genetic predispositions including inborn errors of immunity (IEI) affecting immune response to bacterial pathogens
Target Population
Previously healthy patients without known predisposition or immune deficiency
Care Setting
Clinical and research settings utilizing whole-exome sequencing (WES) for diagnosis and genetic analysis
Key Highlights
WES identified putative disease-causing variants in 42% of previously healthy patients with SBI, revealing inborn errors of immunity.
Most prior genetic studies used candidate-gene approaches; WES allows unbiased discovery of novel genetic variants linked to SBI susceptibility.
Heterogeneity in study designs and variant prioritization methods limits meta-analysis; collaboration is needed for large-scale robust studies.
Guideline-Based Recommendations
Diagnosis
Use whole-exome sequencing as a diagnostic tool in previously healthy patients presenting with severe bacterial infections to identify underlying genetic predispositions.
Exclude patients with known genetic or dysimmune disorders to focus on novel genetic susceptibility factors.
Management
Consider genetic findings from WES to guide personalized management and potential targeted therapies for patients with identified inborn errors of immunity.
Monitoring & Follow-up
Monitor patients with identified genetic variants for infection susceptibility and disease severity to optimize clinical outcomes.
Risks
Recognize the rarity and heterogeneity of genetic variants associated with SBI, which may complicate interpretation and clinical decision-making.
Be aware of potential biases and limitations in current WES studies due to small sample sizes and diverse methodologies.
Patient & Prescribing Data
Previously healthy individuals with severe bacterial infections without prior immune deficiencies
WES can uncover genetic causes that may influence treatment decisions, though specific therapeutic guidelines based on genetic findings remain to be established.
Clinical Best Practices
Apply strict guidelines for variant prioritization to accurately identify disease-causing mutations in WES data.
Collaborate across research teams to increase sample sizes and improve statistical power in genetic studies of SBI.
Integrate genetic findings with clinical phenotypes to enhance diagnosis and management of severe bacterial infections.
